Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucy Chester

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Addiction (Abingdon, England)|April 3, 2025
Commentary on Coelho et al.: Ecological momentary assessments may be key to the future of cannabis studiesLucy Chester, François-Olivier Hebert, Didier Jutras-Aswad
Addiction (Abingdon, England)|February 6, 2020
How experimental cannabinoid studies will inform the standardized THC unitLucy Chester, Edward Chesney, Dominic Oliver, et al.
Cannabis and Cannabinoid Research|May 17, 2021
Synthetic Cannabinoid-Related Deaths in England, 2012-2019Pruntha Yoganathan, Hugh Claridge, Lucy Chester, et al.
Journal of Renal Care|June 4, 2019
Key experiences of primary social groups in Unspecified Kidney DonationAlexis Clarke, Annie Mitchell, Lynsey Williams, et al.
Addiction (Abingdon, England)|October 11, 2023
Cannabidiol does not attenuate acute delta-9-tetrahydrocannabinol-induced attentional bias in healthy volunteers: A randomised, double-blind, cross-over studyDominic Oliver, Amir Englund, Edward Chesney, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 15, 2022
Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratiosAmir Englund, Dominic Oliver, Edward Chesney, et al.
Pharmaceutics|January 8, 2025
Novel Lipid Formulation Increases Absorption of Oral Cannabidiol (CBD)Edward Chesney, Ndabezinhle Mazibuko, Dominic Oliver, et al.
The Lancet. Neurology|March 28, 2016
Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association dataKin Y Mok, Una Sheerin, Javier Simón-Sánchez, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Addiction (Abingdon, England)|April 3, 2025
Commentary on Coelho et al.: Ecological momentary assessments may be key to the future of cannabis studiesLucy Chester, François-Olivier Hebert, Didier Jutras-Aswad
Addiction (Abingdon, England)|February 6, 2020
How experimental cannabinoid studies will inform the standardized THC unitLucy Chester, Edward Chesney, Dominic Oliver, et al.
Cannabis and Cannabinoid Research|May 17, 2021
Synthetic Cannabinoid-Related Deaths in England, 2012-2019Pruntha Yoganathan, Hugh Claridge, Lucy Chester, et al.
Journal of Renal Care|June 4, 2019
Key experiences of primary social groups in Unspecified Kidney DonationAlexis Clarke, Annie Mitchell, Lynsey Williams, et al.
Addiction (Abingdon, England)|October 11, 2023
Cannabidiol does not attenuate acute delta-9-tetrahydrocannabinol-induced attentional bias in healthy volunteers: A randomised, double-blind, cross-over studyDominic Oliver, Amir Englund, Edward Chesney, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 15, 2022
Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratiosAmir Englund, Dominic Oliver, Edward Chesney, et al.
Pharmaceutics|January 8, 2025
Novel Lipid Formulation Increases Absorption of Oral Cannabidiol (CBD)Edward Chesney, Ndabezinhle Mazibuko, Dominic Oliver, et al.
The Lancet. Neurology|March 28, 2016
Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association dataKin Y Mok, Una Sheerin, Javier Simón-Sánchez, et al.
Pageof 1